Finance

Lists
MRNA:NASDAQ
Moderna Inc
$ 136.62
+0.74%
(+1.01) 1D
$ 135.50
-0.82% (-1.12)
After hours
Closed: 9-р сарын 10, 16:00:01 (GMT-4)  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MRNA...
Open
$ 134.86
High
$ 137.13
Low
$ 130.38
Mkt. cap
54.54 тэрбум
Avg. vol.
24.39 сая
Volume
7.87 сая
52-wk high
$ 176.66
52-wk low
$ 22.29
EPS
-$ 7.98
Beta
1.10
Shares outstanding
399.24 сая
No. of employees
5 мян
Open
$ 134.86
High
$ 137.13
Low
$ 130.38
Mkt. cap
54.54 тэрбум
Avg. vol.
24.39 сая
Volume
7.87 сая
52-wk high
$ 176.66
52-wk low
$ 22.29
EPS
-$ 7.98
Beta
1.10
Shares outstanding
399.24 сая
No. of employees
5 мян
News stories
From web sources and news partners
Profile
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern". The company's commercial products are the Moderna COVID-19 vaccine sold under the brand names Spikevax and Mnexspike, a respiratory syncytial virus vaccine sold under the brand name Mresvia, and an influenza vaccine sold under the brand name Mflusiva. The company has 44 treatment and vaccine candidates, of which 37 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines. In 2026, Time ranked Moderna as number one in their World's Most Impactful Companies list. Wikipedia
About Moderna Inc
CEOStéphane Bancel
Employees4.7 мян
Founded9-р сар 2010
Headquarters-
Sector-
Analyst ratings
Based on 18 analysts giving stock ratings to MRNA in the past 3 months
Hold
Buy
3
Hold
13
Sell
2
12-month forecast
Based on 18 Wall Street analysts offering 12 month price targets for MRNA in the last 3 months.
Highest
Current $ 136.62
$ 180.00 (+31.75%)
Average
$ 96.60 (-29.29%)
Lowest
$ 40.00 (-70.72%)
Analyst
Recommendation
Action
Price target
Projected
Date
Simon Baker CFA
Rothschild & Co Redburn
Sell
Downgraded
$ 81.00
-40.7%
09/03/2026
Jasper Hellweg
Argus Research
Buy
Upgraded
$ 180.00
+31.8%
08/27/2026
Alexandria Hammond
Wolfe Research
Hold
Upgraded
-
-
08/25/2026
Eliana Merle
Barclays
Hold
Maintained
$ 125.00
-8.5%
08/24/2026
Michael Yee
UBS
Hold
Maintained
$ 150.00
+9.8%
08/20/2026
Terence Flynn
Morgan Stanley
Hold
Maintained
$ 89.00
-34.9%
08/19/2026
Andrew Tsai
Jefferies
Hold
Reiterated
$ 60.00
-56.1%
08/19/2026
Alec Stranahan
Bank of America Securities
Hold
Upgraded
$ 170.00
+24.4%
08/19/2026
Salveen Richter
Goldman Sachs
Hold
Reiterated
$ 120.00
-12.2%
08/19/2026
Luca Issi
RBC Capital
Hold
Maintained
$ 130.00
-4.8%
08/19/2026
Joseph Stringer
Needham
Hold
Maintained
-
-
08/19/2026
Jessica Fye
J.P. Morgan
Sell
Maintained
$ 77.00
-43.6%
08/21/2026
Courtney Breen
Bernstein
Hold
Reiterated
$ 45.00
-67.1%
08/20/2026
Geoff Meacham
Citi
Hold
Maintained
$ 60.00
-56.1%
08/19/2026
Myles Minter
William Blair
Buy
Upgraded
-
-
08/19/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
$ 77.00
-43.6%
08/06/2026
Tyler Van Buren
TD Cowen
Hold
Maintained
$ 40.00
-70.7%
07/31/2026
Harry Gillis
Berenberg Bank
Hold
Maintained
$ 45.00
-67.1%
07/31/2026
Unknown Analyst
Berenberg Bank
Hold
Maintained
$ 45.00
-67.1%
07/31/2026
Unknown Analyst
J.P. Morgan
Sell
Maintained
$ 40.00
-70.7%
05/20/2026
Cory Kasimov
Evercore ISI
Hold
Maintained
$ 50.00
-63.4%
05/04/2026
Mani Foroohar
Leerink Partners
Sell
Maintained
$ 12.00
-91.2%
02/11/2026
Nico Chen
DBS
Hold
Maintained
$ 45.00
-67.1%
01/28/2026
Last report
2026 оны 7-р сарын 31
Fiscal period
Q2 2026
EPS / Est. (USD)
-$ 1.97 / -$ 2.11
+6.64%beat
Revenue / Est. (USD)
145.00 сая / 102.96 сая
+40.84%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025 оны 9-р сар
2025 оны 12-р сар
2026 оны 3-р сар
2026 оны 6-р сар
Revenue
1.02 тэрбум
678.00 сая
389.00 сая
145.00 сая
Cost of goods sold
1.01 тэрбум
1.23 тэрбум
726.00 сая
738.00 сая
Cost of revenue
1.01 тэрбум
1.23 тэрбум
726.00 сая
738.00 сая
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
268.00 сая
308.00 сая
173.00 сая
216.00 сая
Operating expense
268.00 сая
308.00 сая
173.00 сая
216.00 сая
Total operating expenses
1.28 тэрбум
1.54 тэрбум
899.00 сая
954.00 сая
Operating income
-260.00 сая
-857.00 сая
-510.00 сая
-809.00 сая
Other non operating income
-4.00 сая
-2.00 сая
-
-2.00 сая
EBT including unusual items
-187.00 сая
-799.00 сая
-1.33 тэрбум
-767.00 сая
EBT excluding unusual items
-191.00 сая
-797.00 сая
-455.00 сая
-761.00 сая
Income tax expense
13.00 сая
27.00 сая
9.00 сая
15.00 сая
Effective tax rate
-6.95%
-3.38%
-0.67%
-1.96%
Other operating expenses
-
-
-
-
Net income
-200.00 сая
-826.00 сая
-1.34 тэрбум
-782.00 сая
Net profit margin
-19.68%
-121.83%
-345.24%
-539.31%
Earnings per share
-0.51
-2.11
-3.40
-1.97
Interest and investment income
73.00 сая
70.00 сая
72.00 сая
67.00 сая
Interest expense
-
-8.00 сая
-17.00 сая
-17.00 сая
Net interest expenses
73.00 сая
62.00 сая
55.00 сая
50.00 сая
Depreciation and amortization charges
-
-
-
-
EBITDA
-208.00 сая
-790.00 сая
-451.00 сая
-746.00 сая
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google аппс